PSC Investments, a subsidiary of California based PSC Biotech Corporation, has acquired a high-potency sterile injectable facility from the Morgridge Institute for Research (MIR), a private research institute affiliated with the University of Wisconsin-Madison. The contract manufacturing operation will be named BioTechnique and will be a newly formed subsidiary of PSC Biotech.

The 37,000-square foot sterile injectable fill-finish facility, located in Madison's University Research Park was constructed in 2008 by Mentor Biologics, Inc. and later conveyed to MIR.

The facility will provide specialized filling services for cytotoxic, high-potency, biologic, and other sterile injectable drugs. BioTechnique will be customer ready for sterile liquid and lyophilization fill-finish production in 2015. When fully operational, BioTechnique is expected to employ over 100 technical professionals in Madison, Wisconsin.

Source; PCS Investments